OBAGI MEDICAL acquired by BRIDGEPOINT

Obagi Medical, a medical-grade skincare company positioned in the professional dermatology and aesthetics segment, is being acquired by Bridgepoint as part of a broader consolidation trend across clinical skincare markets. The transaction reflects a strategy focused on building specialised platforms within dermatology and aesthetics, supported by structural growth driven by the medicalisation of skincare routines and the convergence of beauty and healthcare. Bridgepoint aims to build an integrated platform of clinical skincare and aesthetics brands covering a broader spectrum of solutions, from dermatological treatments to injectable aesthetic products. The acquisition of Obagi provides exposure to a leading physician-dispensed brand with a recurring professional customer base and strong alignment with global trends in medicalised skincare. The industrial rationale is based on convergence between medical skincare and injectable aesthetics, with potential synergies in professional distribution, product development and geographic expansion.